Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT00772382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
August 31, 2010
Enrollment
116 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, dialysis, hyperphosphatemia